Startups
Ride Therapeutics
Cambridge, England, United Kingdom
Cambridge biotechnology company developing AI-designed, non-viral delivery carriers for genetic medicines. Its Molecular Logistics platform combines high-throughput nanoparticle engineering and in-vivo screening with a generative model trained on biodistribution measurements. The company reports delivery hits across multiple tissues, including brain and lung; its cystic fibrosis delivery program remains preclinical. Ride emerged from Harvard and Cambridge research, with a UK entity incorporated in 2022 and a public launch in 2023 backed by $8 million in seed funding. In September 2026 the Cystic Fibrosis Foundation announced a commitment of up to $7.3 million for lung delivery development. That conditional commitment is distinct from seed cash already raised.
Founded 2022
Team
 Al KellyBoard Member |
 David WeitzScientific Co-Founder |
 Emer ReynoldsHead of Alliances and Corporate Strategy |
 George Kelly MartinChairman and Co-Founder |
 Samuel CohenChief Executive Officer and Co-Founder · Board Member |
Thomas HughesBoard Member |
 Timothy WelshHead of Platform Technology and Co-Founder |
 Tuomas KnowlesScientific Co-Founder · Board Member |